Groundbreaking ceremony for the new biopharmaceutical production facility of Boehringer Ingelheim with approximately 500 additional jobs.
With Chancellor Christian Kern und Vienna Executive City Councillor Renate Brauner in attendance, Boehringer Ingelheim today held the groundbreaking ceremony for its new biopharmaceutical production facility in Vienna-Meidling. A sum of nearly 700 million euros has been set aside for the project (including infrastructure). This is the largest single investment in the company’s history, and the largest commercial investment in Vienna since 1979, when General Motors built a factory in Aspern. The new facility will commence operation in 2021, producing biopharmaceutical medications based on cell cultures.
500 new jobs in Vienna-Meidling
As part of the expansion, Boehringer Ingelheim will create approximately 500 additional jobs for highly skilled workers in Vienna. “The positions we will fill are quite diverse, ranging from process and biopharmaceutical technicians to lab technicians and sales staff,” says Lattorff. The first employees have already been hired to plan and build the new production sites. Boehringer Ingelheim, a German family-owned firm, already employs more than 1,600 people in Vienna, and that number will grow to approximately 2,100 in the years ahead.
More Information: www.boehringer-ingelheim.at
Vienna, 6th April 2017